Quantcast

GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the Third Quarter Ending September 30th, 2020 and Host Conference Call on November 3rd, 2020

LONDON and CARLSBAD, Calif., Oct. 22, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on November 3rd, 2020 its financial results and operational progress for the third quarter ending September 30th, 2020. GW will also host a conference call the same day at 8:30 a.m. EST. Conference call information will be provided in the financial results press release and on the Company website (www.gwpharm.com) in the investor section. A replay of the call will also be available through the Company’s website shortly after the call.

About GW Pharmaceuticals plc and Greenwich Biosciences, Inc.
Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company’s lead product, EPIDIOLEX® (cannabidiol) oral solution is commercialized in the U.S. by its U.S. subsidiary Greenwich Biosciences for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome or tuberous sclerosis complex (TSC) in patients one year of age and older. This product has received approval in the European Union under the tradename EPIDYOLEX® for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in conjunction with clobazam in patients two years and older and is under EMA review for the treatment of TSC. The Company is also carrying out a Phase 3 trial in Rett syndrome and has a deep pipeline of additional cannabinoid product candidates, including nabiximols, for which the Company is advancing multiple late-stage clinical programs in order to seek FDA approval in the treatment of spasticity associated with multiple sclerosis and spinal cord injury, as well as for the treatment of PTSD. (Read more…) The Company has additional cannabinoid product candidates in Phase 2 trials for autism and schizophrenia. For further information, please visit www.gwpharm.com.

Enquiries:

GW Pharmaceuticals plc  
Stephen Schultz, VP Investor Relations (U.S.) 917 280 2424 / 401 500 6570

One thought on “GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the Third Quarter Ending September 30th, 2020 and Host Conference Call on November 3rd, 2020

  • October 23, 2020 at 3:58 pm
    Permalink

    After my Multiple Sclerosis diagnosis, I learnt about Mayaka Natural Clinic and their effective MS Formula treatment through an MS support group on facebook, I quickly started on the treatment. Few months on the treatment, my tremors mysterious stopped, had improvement with balance and walking. When I completed the treatment, symptoms were gone, this MS Herbal treatment relieved my symptoms significantly. Thank you for giving those of us with Multiple sclerosis a new hope (ww w. mayakanaturalclinic. c om).

    Reply

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.